I've not seen this posted so apologies if I have missed but within the fundraising RNS is a link to the commercial prospectus that accompanied the sale. It provides a neat summary of the key areas of business (updating some areas from the annual report). It is available at: https://www.sec.gov/Archives/edgar/data/1723069/000121390020020182/ea124966-424b5_tizianalife.htm#T24
Eg Stemprinter summary therein.
StemPrintER is a multi-gene signature assay intended for use as a prognostic tool in patients with estrogen-receptor positive ER+/HER2 negative breast cancers. This in-vitro prognostic test can be used in conjunction with clinical evaluation to identify those patients at increased risk for early and/or late metastasis to help physicians distinguish ER+/HER2 negative patients. Two posters were selected for presentation at virtual ASCO 2020 Conference. One demonstrating the superiority of StemPrintER stem cell based genomic prognostic tool versus the market leader, Oncotype DX, in predicting recurrence in ER+/HER2- postmenopausal breast cancer patients was selected for discussion session. The second poster describing results on prediction of distant recurrence using a next generation StemPrintER model, named SPARE, presented in a separate ASCO session, showed even more refined accuracy than standard clinicopathological markers in predicting risk of distant recurrence. Both posters were authored by a team of scientists from the European Institute of Oncology in Milan, and the head-to-head comparison of StemPrintER with Oncotype DX was conducted in collaboration with the Royal Marsden Hospital and Queen Mary University in London.
On July 1, 2020, we announced plans to continue with “demerger” of the StemPRintER© technology and spin-off into a separate company. This event followed announcement on May 29, 2020 of results from a study showing that StemPRintER outperformed Oncotype DX in 10-year risk prediction in more than 800 ER+/HER2- postmenopausal breast cancer patients in the analysis, including in lymph node-negative (N0) and 1 to 3 lymph node-positive (N1-3) patients.
So.. We are to expect a II shareholder RNS in next day or so?
So the polygon and kite lake shorts were closed after the RNS yesterday. Great news for holders given all the games the shorter had been playing. Plus I'm hoping the board can have less of the antagonism and schadenfreude that accompanied them. That's me being polite of course.
Meanwhile onwards and upwards.
Great RNS. I always had faith
Overall good news, and in line with expectations, so reassuring for the future cash and profit generation. I would have liked a lot more detail about the plans (perhaps will follow on their website or elsewhere?) but c'est la vie.
I agree that the RNS is boring. Contrast it with GGPs of yesterday. But in the wider scheme of things the start of production is massive. Credit where due for the acquisition and production delivery of this game-changing asset.
Antharry,
I have no doubts that production is imminent. The licenses are all in place, the equipment is in place. The staffing will have been recruited. The funding to start production is in place. Meanwhile there is a monster asset with enviable metal resources (with metal prices at recent highs) ready to go, with buyer lined up for up to 550T (or was it 450?). They will need the assay results for refinancing etc, but in terms of dependencies no I am not worried about a delay to production. At this stage, if there is one it would in my estimation be a short delay..e.g. a matter of days - which in the long run is not of any concern.
Encourage bod share buys... Any reason they can't? I second the interview suggestion.
I have written to the company to encourage further details about the BP project, in terms of costs, revenues,assay, ramping up plans, etc. With production this month, hopefully this will finally take off given the quality and quantity of the mine resources. GLA
Hi Trilla. You did well indeed. That would have been unfortunate timing. I recently bought in on the basis that this looks like the bottom and the future looks incredibly positive. Once the company has news, which I hope they align with some decent marketing, I anticipate a decent rise. Longer term outlook is even better of course.
Brent 43.75... Decent rise today.
Ah Brent price increase... helpful as a little more positive thought needed on this board (easy to say ha). I remain hopeful that a positive RNS next week will provide the boost we need. Increased stable production, profit. hmm...
Thanks Chester
I'd like the company to update on some of their projections in time. I wonder to what extent CV19 has impacted on expansion and sales. Hopefully a short term delay, certainly Europe market is largely up and running again.
Investing is a balance of risks and rewards. Notwithstanding what has come before, this company, at this price is IMO, a strong buy and hold. I'm a researcher by trade. DYOR.People are still questioning start of production. I understand, as until it is producing, it isn't. It is therefore a binary point. I was keen to buy in before production; because the market will IMO recognise the binary change also. With the company using RNS, interview, and tweets to confirm that we remain on course for production this month (which is not contingent on chinese equipment imports) I will keep the faith. Plus at this stage, any small delay is not a major concern in the long. Frankly I am excited. I still wish I'd bought TILS though ha. GLA
The fundraise, as stated in the 22 May circular (see TRX website) would contribute to...:
.. the addition of two sterile packaging clean rooms in the existing facility over a six month period. Once fully
operational, these additional clean rooms are expected to increase the Group’s current BioRinse processing capacity by c.50% and thereby significantly increase the maximum serviceable revenue for the BioRinse product portfolio.
and..
It is envisaged that phase two of the expansion programme will entail a further potential ten clean rooms, in the new facility adjacent to the current manufacturing site, expected to take approximately 12 months to complete. The Company intends to bring this new capacity on stream in a managed process to meet demand. Once fully operational, it is expected that this
completed expansion programme will increase the Company’s revenue generation potential by up to c.$36m per year
Reiterating the long term hold for me here.
All best